INTERCURE
Sector: Healthcare & Life Sciences
About INTERCURE
InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest-growing cannabis company outside of North America.
Products
- Description: Through its wholly owned subsidiary Canndoc Ltd.
- InterCure is Israel’s largest licensed cannabis producer and a pioneer in delivering GMP-certified.
- pharmaceutical-grade medical cannabis products.
- InterCure has created a vertically integrated “seed-to-sale” ecosystem that spans cultivation.
- manufacturing.
- and nationwide distribution. The company owns and operates Givol - Israel’s premier medical cannabis pharmacy chain - as well as Leon Pharm.
- both serving tens of thousands of patients with access to high-quality pharmaceutical-grade medical cannabis products.
- expert pharmaceutical guidance.
- and personalized patient care.
Latest Company Updates
- Form 6-K- Financial and operating results for the first half of 2025
- Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
- Form 6-K-InterCure Announces FY2024 Results and Provides Q1 2025 Update:Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million,Strong Start to 2025
- FORM 20-F
- InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak